Q1 2025 Earnings Forecast for Haemonetics Co. Issued By Zacks Research (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Haemonetics in a research note issued to investors on Tuesday, August 6th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $1.03 per share for the quarter, up from their prior estimate of $1.02. The consensus estimate for Haemonetics’ current full-year earnings is $4.57 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.11 EPS, Q3 2025 earnings at $1.20 EPS, FY2025 earnings at $4.54 EPS, Q2 2026 earnings at $1.29 EPS, FY2026 earnings at $5.02 EPS, Q1 2027 earnings at $1.64 EPS and FY2027 earnings at $6.02 EPS.

HAE has been the subject of a number of other research reports. Barrington Research lifted their price objective on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. JMP Securities lifted their price target on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Finally, Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research note on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $109.50.

Haemonetics Stock Down 10.8 %

NYSE:HAE opened at $76.43 on Wednesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. The company’s fifty day moving average price is $86.64 and its 200-day moving average price is $84.18. Haemonetics has a 1-year low of $70.74 and a 1-year high of $97.97. The firm has a market capitalization of $3.89 billion, a P/E ratio of 33.38, a PEG ratio of 1.64 and a beta of 0.29.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. Haemonetics’s quarterly revenue was up 12.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 EPS.

Insiders Place Their Bets

In other news, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the sale, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the sale, the insider now owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the transaction, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,523 shares of company stock worth $2,812,120. 1.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Haemonetics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock worth $1,956,000 after buying an additional 838 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in Haemonetics during the fourth quarter worth about $1,223,000. Keene & Associates Inc. boosted its holdings in Haemonetics by 3.1% in the 4th quarter. Keene & Associates Inc. now owns 8,780 shares of the medical instruments supplier’s stock valued at $751,000 after purchasing an additional 268 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in shares of Haemonetics by 345.4% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 44,561 shares of the medical instruments supplier’s stock valued at $3,810,000 after buying an additional 34,556 shares during the period. Finally, California Public Employees Retirement System increased its holdings in shares of Haemonetics by 36.9% during the 4th quarter. California Public Employees Retirement System now owns 229,717 shares of the medical instruments supplier’s stock worth $19,643,000 after buying an additional 61,935 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.